公开(公告)号：CY1117484T1

公开(公告)日：2017-04-26

申请号：CY161100389

申请日：2016-05-10

Applicant: THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES

Inventor： GUPTA SHANKER

IPC: C07F5/02 ,  A61K31/69 ,  A61K38/00 ,  A61K38/05 ,  A61P29/00 ,  A61P35/00 ,  C07C7/00 ,  C07F5/04 ,  C07K5/06 ,  C07K5/078 ,  C07K5/08 ,  C07K7/02

Abstract: Ηπαρούσαεφεύρεσηπαρέχεισταθερέςενώσειςπουπαρασκευάζονταιαπόβορονικόοξύκαιλυοφιλοποιημένεςενώσειςαυτούμετύπο (1) στονοποίοταΖ1 καιΖ2 είναιτμήματαπουπροέρχονταιαπόσάκχαρο. Ηεφεύρεσηπαρέχειεπίσηςμεθόδουςγιατηνπαρασκευήτέτοιωνενώσεων. Ηλυοφιλοποίησηενόςμίγματοςπουπεριέχειμιαένωσηβορονικούοξέοςκαιένατμήμαπουπροέρχεταιαπόσάκχαροπαράγειμιασταθερήσύνθεσηπουαπελευθερώνειεύκολατηνένωσητουβορονικούοξέοςκατάτηνανασύστασησευδατικάμέσα.

公开(公告)号：ES2604662T3

公开(公告)日：2017-03-08

申请号：ES10179052

申请日：1999-06-23

Applicant: THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES ,  THE BOARD OF TRUSTEES OF THE UNIV ILLINOIS

Inventor： ERICKSON JOHN W ,  GULNIK SERGEI V ,  MITSUYA HIROAKI ,  GHOSH ARUN K

IPC: C07D493/04 ,  G01N33/15 ,  A61K31/34 ,  A61K31/445 ,  A61K31/4525 ,  A61P31/18 ,  A61P37/04 ,  A61P43/00 ,  C07D491/04 ,  C07D495/04 ,  C12Q1/02 ,  C12Q1/37

Abstract: Una cantidad eficaz inhibidora de la resistencia de un compuesto de fórmula: **Fórmula** en el que: (i) A es **Fórmula** R3 es fenilo, R5 es isobutilo, y Ar es fenilo sustituido con un grupo m-hidroxilo, un grupo m- o p-hidroximetilo, o un grupo p-aminometilo; o (ii) A es**Fórmula** R3 es R5 es isobutilo, y Ar es p-metoxifenilo; (iii) A es **Fórmula** R3 es fenilo, R5 es **Fórmula** y Ar es m-metoxifenilo; o (iv) A es **Fórmula** R3 es fenilo, R5 es isobutilo, y Ar es p-aminofenilo para su uso en el tratamiento de un mamífero infectado por el VIH que está infectado con un VIH mutante, en combinación con un agente antiviral seleccionado del grupo que consiste en ritonavir, indinavir y saquinavir en un vehículo farmacéuticamente aceptable, en el que dicho tratamiento previene la aparición de resistencia a los medicamentos debido a mutaciones adicionales.

公开(公告)号：ZA201006843B

公开(公告)日：2012-03-28

申请号：ZA201006843

申请日：2010-09-27

Applicant: THE UNIV OF MIAMI ,  THE UNITED STATES OF AMERICA REPRESENTED BY THE UNITED STATES DEOARTMENT OF VETERAN'S AFFAIRS

Inventor： SCHALLY ANDREW V ,  VARGA JOZSEF L ,  ZARANDI MARTA ,  CAI REN ZHI

IPC: A61K20060101 ,  C07K20060101 ,  G01N20060101

Abstract: Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.

公开(公告)号：AU2007203321C1

公开(公告)日：2011-12-08

申请号：AU2007203321

申请日：2007-07-17

Applicant: UNIV ILLINOIS ,  THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： GHOSH ARUN K ,  GULNIK SERGEI V ,  ERICKSON JOHN W ,  HIROAKI MITSUYA

IPC: A61K31/335 ,  A61P31/18 ,  C12Q1/00

Abstract: The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity 5 relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of-thes emergence of drug resistance in therapy.

公开(公告)号：HK1149936A1

公开(公告)日：2011-10-21

申请号：HK11103293

申请日：2011-03-31

Applicant: THE UNITED STATES OF AMERICA REPRESENTED BY THE SE

Inventor： GUPTA SHANKER

IPC: A61K9/19 ,  C07F20060101 ,  A61K20060101 ,  A61K31/69 ,  A61K38/00 ,  A61K38/14 ,  A61P20060101 ,  A61P29/00 ,  A61P31/18 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07C20060101 ,  C07F5/02 ,  C07F5/04 ,  C07F5/05 ,  C07H9/00 ,  C07K20060101 ,  C07K5/06 ,  C07K5/062 ,  C07K5/065 ,  C07K5/078 ,  C07K5/08 ,  C07K5/083 ,  C07K5/097 ,  C07K5/117 ,  C07K7/02 ,  C07K9/00

公开(公告)号：AU2005289414B2

公开(公告)日：2010-12-09

申请号：AU2005289414

申请日：2005-09-27

Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUM

Inventor： DEROSA FRANK ,  HRABIE JOSEPH A ,  CITRO MICHAEL L ,  KEEFER LARRY K

IPC: C08F8/30 ,  A61K31/78

Abstract: The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N2O2− group, wherein the N2O2− group is attached directly to the polyacrylonitrile backbone, to a specific location on or within the mammal in an amount effective to treat the biological disorder or promote angiogenesis.

公开(公告)号：AU2009228244A1

公开(公告)日：2009-10-01

申请号：AU2009228244

申请日：2009-03-26

Applicant: THE UNITED STATES OF AMERICA REPRESENTED BY THE UNITED STATES DEPT OF VETERANS AFFAIRS ,  THE UNIV OF MIAMI

Inventor： SCHALLY ANDREW V ,  MARTA ZARANDI ,  VARGA JOZSEF L ,  CAI RENZHI

IPC: C07K14/60 ,  A61K38/25 ,  G01N33/74

Abstract: Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.

公开(公告)号：AU2004203609B2

公开(公告)日：2009-10-01

申请号：AU2004203609

申请日：2004-08-04

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEA

Inventor： SCHILLER JOHN T ,  LOWY DOUGLAS R ,  KIRNBAUER REINHARD

IPC: G01N33/53 ,  A61K39/00 ,  A61K39/12 ,  A61K39/23 ,  A61P17/12 ,  A61P31/12 ,  A61P31/20 ,  A61P35/00 ,  C07K14/025 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N7/04 ,  C12N15/09 ,  C12N15/37 ,  C12P21/02 ,  C12Q1/70 ,  C12R1/91 ,  G01N33/566 ,  G01N33/569

Abstract: Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.

公开(公告)号：AU2006315760A1

公开(公告)日：2007-05-24

申请号：AU2006315760

申请日：2006-11-09

Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY

Inventor： BATES SUSAN E ,  SISSUNG TRISTAN M ,  FIGG WILLIAM D ,  PIEKARZ RICHARD L ,  SPARREBOOM ALEXANDER

IPC: C12Q1/68

Abstract: The invention provides methods and materials for screening for polymorphic variants in ABCB1 and diagnosing altered susceptibilities for drug-induced heart rhythm irregularities based on the same. These methods allow better treatment regimens for using drugs that bind a protein encoded by the ABCB1 and/or induce heart rhythm irregularities such as the anti-cancer drug FK228.

公开(公告)号：AU2006258035A1

公开(公告)日：2006-12-21

申请号：AU2006258035

申请日：2006-06-07

Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY

Inventor： GRUNDT PETER ,  KATZ JONATHAN L ,  NEWMAN AMY HAUCK

IPC: A61K31/439 ,  A61P25/30 ,  C07D451/04

Abstract: Disclosed are benztropinamine analogs having the formula I (I) in which E is NR 1 , S, or CH 2 ; B is NR 4 , O, or CH 2 ; m=1 to 5; n=1 to 3; Ar is a C 5 -C 20 monocyclic aryl group or a C 10 -C 20 bicyclic aryl group or a heteroaryl group having 2 to 6 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, and any combination thereof; and bond "a" can be of alpha, beta, or alpha/beta configuration, wherein R 1 to R 5 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.